Y-27632 dihydrochloride: A Selective ROCK1/2 Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride (SKU: A3008) is a potent, cell-permeable small molecule that selectively inhibits Rho-associated protein kinases ROCK1 and ROCK2, with IC₅₀ values of ~140 nM and Ki values of 300 nM, respectively [ApexBio Product]. It demonstrates over 200-fold selectivity against other kinases, including PKC, MLCK, and PAK. Y-27632 is widely used in research to modulate cytoskeletal dynamics, enhance stem cell viability, and suppress tumor invasion [Q-VD 2022]. The compound is highly soluble in DMSO, ethanol, and water under controlled conditions. Its research use has expanded to disease modeling, cell proliferation assays, and the investigation of Rho/ROCK signaling in health and disease [Prostigmin 2023].

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases central to the Rho/ROCK signaling pathway. They regulate actin cytoskeleton reorganization, cell shape, migration, and proliferation. Aberrant ROCK signaling is implicated in cancer progression, fibrosis, and neurodegenerative diseases. Selective inhibition of ROCK1/2 by Y-27632 blocks Rho-mediated formation of stress fibers and focal adhesions, providing a direct method for dissecting cytoskeletal and cell cycle mechanisms [Q-VD 2022]. In stem cell biology, ROCK inhibition prevents dissociation-induced apoptosis, supporting the survival of pluripotent stem cells during passage and reprogramming [America Peptides 2023].

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride acts as a competitive ATP-binding inhibitor, targeting the catalytic domains of ROCK1 and ROCK2. At nanomolar concentrations (IC₅₀ ≈ 140 nM for ROCK1; Ki = 300 nM for ROCK2), it prevents substrate phosphorylation necessary for actin-myosin contractility. This leads to suppression of stress fiber formation and focal adhesion assembly in vitro. Y-27632 exhibits >200-fold selectivity over unrelated kinases such as protein kinase C (PKC), myosin light chain kinase (MLCK), and p21-activated kinase (PAK), minimizing off-target effects [ApexBio Product]. Functionally, this blockade disrupts cytokinesis, modulates cell cycle progression (G1 to S phase), and impedes migration and invasion in cancer models.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a Ki of 300 nM under cell-free assay conditions (ApexBio, product page).
• It exhibits >200-fold selectivity against kinases such as PKC, MLCK, and PAK, as confirmed by kinase profiling assays (ApexBio, product page).
• In vitro, Y-27632 suppresses Rho-induced formation of actin stress fibers in fibroblasts after 1–2 hours of exposure at 10 μM in serum-containing media (ApexBio, product page).
• Y-27632 reduces proliferation of human prostatic smooth muscle cells in a concentration-dependent manner (10 μM, 24h) (ApexBio, product page).
• In mouse models, systemic administration of Y-27632 (10 mg/kg, intraperitoneal) diminishes tumor invasion and metastasis, correlating with reduced ROCK activity in tumor tissue (ApexBio, product page).
• Solubility benchmarks: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C, enhanced by warming to 37°C or ultrasonication (ApexBio, product page).
• Y-27632 supports maintenance and passage of human pluripotent stem cells, reducing apoptosis and enhancing colony formation (Prostigmin 2023, internal article).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is a standard tool in cytoskeletal, stem cell, and cancer research. Its high selectivity enables precise modulation of Rho/ROCK signaling with minimal interference from other kinase pathways.

• Cytoskeletal studies: Disrupts stress fiber and focal adhesion formation in multiple cell types.
• Stem cell research: Enhances viability of pluripotent and neural progenitor cells during single-cell dissociation and culture [America Peptides 2023].
• Cancer biology: Inhibits cell migration, invasion, and metastasis in preclinical tumor models.
• Disease modeling: Used in advanced neuro-gut and iPSC-based disease models [Q-VD 2022].

This article details expanded use cases and solubility data, extending the procedural context found in previous practical guides by integrating recent evidence on in vivo antitumoral effects and optimized workflow strategies.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit kinases outside the ROCK family at relevant research concentrations; off-target effects are minimal but not absent at high doses.
• It does not reverse established fibrosis or tumor burden in vivo; effects are preventive or modulatory rather than curative.
• Long-term storage of Y-27632 in solution (> several months) at room temperature leads to degradation; solid-state storage at ≤4°C is required.
• Cell viability enhancement in stem cell cultures is context-dependent and may not generalize to all cell types.
• Not suitable as a therapeutic agent in humans; approved for research use only.

Workflow Integration & Parameters

Y-27632 dihydrochloride (A3008) is supplied as a solid. For maximum solubility, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Solubility is enhanced by warming to 37°C or ultrasonication. Prepare working stocks at 10–20 mM in DMSO and aliquot for storage at -20°C. Avoid repeated freeze-thaw cycles and prolonged storage in solution.

Typical concentrations for in vitro assays are 10 μM for cytoskeletal or proliferation studies and 10–50 μM for stem cell viability protocols. For in vivo models, published studies use 10 mg/kg via intraperitoneal injection. Optimization may be required for specific applications. Refer to the Y-27632 dihydrochloride product page for detailed protocols and safety data.

This article updates and clarifies advanced experimental designs previously discussed in 'Advanced Insights into ROCK Inhibition' by including recent benchmarks on solubility and storage stability.

Conclusion & Outlook

Y-27632 dihydrochloride is a robust, selective inhibitor of ROCK1 and ROCK2 that has transformed cytoskeletal, stem cell, and cancer research. Its high selectivity, reproducible potency, and flexible solubility profile enable wide-ranging experimental applications. Future studies may further delineate its role in disease modeling and regenerative medicine. For current use, strict adherence to storage and preparation protocols ensures maximal reproducibility and biological effect.